Cervical cancer rates are on the rise among younger women, owing in part to a lack of screening and prevention.

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...

IN a powerful response to the World Health Organisation’s call for the global elimination of cervical cancer by 2030, ...

Adding adjuvant chemotherapy to radiotherapy did not lead to a significant survival benefit over radiotherapy alone in women ...

As part of an NHS scheme aimed at eradicating cervical cancer by 2040, DIY smear tests for women could be introduced in ...

A report from the CDC shows cervical precancerous lesions dropped 80% in 20-24 year old women screened for cervical cancer ...

In an interview, Ncube said that the AI tool for screening cancer is a product of his Master’s Degree thesis. The thesis was ...

In Côte d'Ivoire, nearly 90% of cervical cancer screenings are conducted through self-testing, empowering women to take charge of their health. This approach allows for detection in a private, ...

Of 8,000 women who underwent cervical cancer screening in recent months, reports of 450 came positive, who need further ...

The international community has been called upon to scale up cervical cancer interventions and progress against the only ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...